

New Medicines Subgroup: Processes for NICE TAs

Cheshire and Merseyside Area Prescribing Group (APG)

Grey, Black or Red RAG rating

| Situation | Actions |
|---|---|
| <p>1. Drug launched and is for NMSG action</p> | <p>Grey statements will not be routinely issued, unless subgroup identify need, on a case-by-case basis (e.g. where further information is required for clinicians or patients)</p> |
| | <p>a) Subgroup agree grey statement not required:</p> <ul style="list-style-type: none"> • Subgroup Chair to co-ordinate updates to legacy formularies • Grey RAG in formulary, pending publication of NICE TA. Hyperlink to NICE. • Grey RAG summary to next APG meeting for information only • No requirement to circulate for APG consultation |
| | <p>b) Subgroup agree need for grey statement:</p> <ul style="list-style-type: none"> • Subgroup Chair / nominated subgroup member to author • Draft grey statement produced. Hyperlink to NICE and include any other relevant information • Grey statement to be proof read and uploaded • Subgroup Chair to co-ordinate updates to legacy formularies • Grey statement to next APG meeting for information only, ICB approval not required • No requirement to circulate for APG consultation |
| <p>2. FAD / TA published</p> | |

Go to **situation 3**

**For drugs relevant to APG pathways,
the Subgroup Chair will inform FGSG
at the point of FAD publication**

3. Is drug recommended by NICE?

If no – go to **situation 4**

If yes – go to **situation 5**

**4. Drug is not
recommended by NICE**
(negative FAD / TA)

- Provisional **Black** RAG assigned
- Black statements will not be routinely issued, unless subgroup identify need, on a case-by-case basis (e.g. where further information is required for clinicians or patients)
- Author to bring proposal to NMSG, using Black RAG report
- NMSG agree RAG and need for statement
- Not necessary to 'information gather' from LMC and LPC

Negative FAD - when TA published return to **situation 2**

Negative TA – continue with **situation 4**

- Bring RAG report / statement back to NMSG when TA published
- Agree final APG document
- Prepare for APG:
 - Cover sheet required for Black statements but not required for RAG reports
 - DSS not required for any Black RAG documents
 - Subgroup Chair / nominated deputy to present at APG
- Black RAG report / statement taken to APG for recommendation
- Black RAG report / statement sent to ICB for approval
- For Black RAG reports, there will be no statement to upload. A Black RAG will be assigned in the formulary with a link to the TA. Subgroup Chair to co-ordinate updates to legacy formularies after ICB approval is received.

| | |
|---|---|
| | <ul style="list-style-type: none"> For Black statements, the statement will be uploaded and formulary updated by after ICB approval is received. Subgroup Chair to co-ordinate updates to legacy formularies. |
| <p>5. Drug <u>is</u> recommended by NICE (positive FAD / TA)</p> | <p>Determine RAG – see situation 6 [and situation 7]</p> |
| <p>6. Drug is not suitable for primary care prescribing</p> <p>[e.g. tariff-excluded high cost drug with commercial arrangement, for specialist use only; in-tariff drug, for specialist use only]</p> | <ul style="list-style-type: none"> Subgroup Chair informs author of FAD / TA publication Provisional Red RAG assigned Red statements will not be routinely issued, unless subgroup identify need, on a case-by-case basis (e.g. where further information is required for clinicians or patients, or implementation information is required) Author to bring proposal to NMSG, using Red RAG report NMSG agree RAG and need for statement Identify any areas for further investigation i.e. within trusts Not necessary to routinely 'information gather' from LMC and LPC Chair to escalate any potential issues / barriers to ICB <p style="text-align: center;">↓</p> <p><u>TAs with 90 day implementation deadline:</u></p> <ul style="list-style-type: none"> Bring RAG report / statement back to NMSG when TA published, including any feedback from further investigation (if relevant). <p><u>TAs with 30 day implementation deadline:</u></p> <ul style="list-style-type: none"> In a situation where the implementation deadline will breach if the TA is delayed to the next NMSG meeting, the proposal / statement can be progressed straight to the APG meeting if the subgroup have already considered the proposal / statement from the FAD and no further issues have identified. The Chair will inform the subgroup if this action is taken. |

- If the FAD has not already been considered by the subgroup, it may be necessary to agree appropriate action with the subgroup and circulate the proposal / statement by email if necessary.



- Costing information added from NICE resource impact statement / template
- Agree final document
- Complete Decision Support Summary (DSS) if required
- Prepare for APG
 - Cover sheet required for Red statement but not required for RAG report
 - DSS included (if necessary)
 - Subgroup Chair / nominated deputy to present at APG
- Red RAG report / statement taken to APG for recommendation
- For Red statement only - final amendments, if necessary, to be made by author or subgroup Chair
- Red RAG report / statement sent to ICB for approval
- For Red RAG reports, there will be no statement to upload. A Red RAG will be assigned in the formulary with a link to the TA. Subgroup Chair to co-ordinate updates to legacy formularies after ICB approval is received.
- For Red statements, the statement will be uploaded and formulary updated by after ICB approval is received. Subgroup Chair to co-ordinate updates to legacy formularies.